NRx Pharmaceuticals (NRXP) Competitors $1.79 -0.08 (-4.28%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.95 +0.16 (+9.16%) As of 04/4/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. SAVA, DERM, ALEC, LXEO, TELO, GNLX, NLTX, JMAC, ENTA, and EPRXShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Cassava Sciences (SAVA), Journey Medical (DERM), Alector (ALEC), Lexeo Therapeutics (LXEO), Telomir Pharmaceuticals (TELO), Genelux (GNLX), Neoleukin Therapeutics (NLTX), Maxpro Capital Acquisition (JMAC), Enanta Pharmaceuticals (ENTA), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Cassava Sciences Journey Medical Alector Lexeo Therapeutics Telomir Pharmaceuticals Genelux Neoleukin Therapeutics Maxpro Capital Acquisition Enanta Pharmaceuticals Eupraxia Pharmaceuticals NRx Pharmaceuticals (NASDAQ:NRXP) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do insiders & institutionals have more ownership in NRXP or SAVA? 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to NRXP or SAVA? In the previous week, NRx Pharmaceuticals had 7 more articles in the media than Cassava Sciences. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 3 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.58 beat NRx Pharmaceuticals' score of 0.14 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor NRXP or SAVA? Cassava Sciences received 76 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformNRx PharmaceuticalsOutperform Votes22100.00% Underperform VotesNo VotesCassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Is NRXP or SAVA more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -449.16% Cassava Sciences N/A -88.05%-64.98% Which has stronger earnings & valuation, NRXP or SAVA? Cassava Sciences is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$30.15M-$2.41-0.74Cassava SciencesN/AN/A-$97.22M-$1.45-0.90 Do analysts prefer NRXP or SAVA? NRx Pharmaceuticals currently has a consensus price target of $28.25, suggesting a potential upside of 1,478.21%. Cassava Sciences has a consensus price target of $54.50, suggesting a potential upside of 4,092.31%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than NRx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, NRXP or SAVA? NRx Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.48, suggesting that its stock price is 248% less volatile than the S&P 500. SummaryNRx Pharmaceuticals beats Cassava Sciences on 10 of the 16 factors compared between the two stocks. Remove Ads Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.28M$6.34B$5.25B$7.12BDividend YieldN/A2.84%4.89%4.06%P/E Ratio-0.846.7721.2317.48Price / SalesN/A187.01355.0585.34Price / CashN/A65.6738.1834.64Price / Book-1.305.576.243.79Net Income-$30.15M$141.67M$3.20B$247.48M7 Day Performance-11.82%-11.46%-8.42%-6.72%1 Month Performance-16.36%-16.54%-4.82%-11.45%1 Year Performance-66.23%-18.09%2.58%-7.78% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals2.4623 of 5 stars$1.79-4.3%$28.25+1,478.2%-65.6%$30.28MN/A-0.842Analyst ForecastNews CoverageSAVACassava Sciences3.7703 of 5 stars$2.80-1.4%$111.50+3,882.1%-93.7%$137.20MN/A-2.0330Short Interest ↓Gap DownDERMJourney Medical2.3928 of 5 stars$6.54+13.9%$9.67+47.8%+64.9%$136.62M$57.77M-6.9690Gap DownHigh Trading VolumeALECAlector3.6351 of 5 stars$1.37+1.5%$3.50+155.5%-82.3%$135.75M$100.56M-0.81270Gap DownLXEOLexeo Therapeutics3.0004 of 5 stars$4.09+50.9%$23.60+477.0%-82.2%$135.24M$650,000.00-1.2958Gap DownHigh Trading VolumeTELOTelomir Pharmaceuticals1.3963 of 5 stars$4.53-0.7%$15.00+231.1%-59.9%$134.83MN/A-7.811GNLXGenelux1.1012 of 5 stars$3.89-1.0%$18.25+369.2%-49.5%$134.35M$8,000.00-4.0910Earnings ReportAnalyst RevisionNews CoverageNLTXNeoleukin TherapeuticsN/A$14.21-6.7%N/A-77.3%$133.55MN/A-4.5790News CoverageHigh Trading VolumeJMACMaxpro Capital AcquisitionN/A$9.90-4.7%N/A+1,233.3%$132.94MN/A0.002,021ENTAEnanta Pharmaceuticals3.9201 of 5 stars$6.20-1.7%$17.25+178.2%-70.8%$132.27M$66.59M-1.25160Gap DownEPRXEupraxia Pharmaceuticals1.7694 of 5 stars$3.65-4.6%$10.50+188.1%N/A$129.93MN/A-5.0629Upcoming EarningsGap Up Remove Ads Related Companies and Tools Related Companies Cassava Sciences Alternatives Journey Medical Alternatives Alector Alternatives Lexeo Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Genelux Alternatives Neoleukin Therapeutics Alternatives Maxpro Capital Acquisition Alternatives Enanta Pharmaceuticals Alternatives Eupraxia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRXP Stock Free NRXP Stock Alerts